Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
276 SEK | -0.14% |
|
+2.00% | +3.37% |
19/06 | Sobi Wins EU Approval for Hemophilia A Drug Altuvoct | MT |
19/06 | European Commission Grants Sobi® Marketing Authorisation for Altuvoct? for Treatment of Haemophilia A | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.37% | 896.24Cr | |
+2.52% | 9.4TCr | |
-3.42% | 3.77TCr | |
-12.43% | 3.3TCr | |
+75.98% | 2.83TCr | |
-11.70% | 1.62TCr | |
+1.53% | 1.43TCr | |
-12.82% | 1.14TCr | |
+190.36% | 1.1TCr | |
-54.07% | 925.7Cr |
- Stock Market
- Equities
- SOBI Stock
- News Swedish Orphan Biovitrum AB
- Sobi's Growth Potential Remains 'Tremendous' Amid Conservative FY24 Outlook, RBC Says